|
ORIGINAL ARTICLE |
|
|
|
Year : 2018 |
Volume
: 29 | Issue : 6 | Page
: 1280-1289 |
|
Assessment of left ventricular mass changes after arteriovenous fistula surgical banding in end-stage renal disease
Camilo Cortesi1, Juan C Duque2, Sedki Mai1, Laisel Martinez3, Adriana Dejman2, Roberto Vazquez-Padron3, Loay Salman4, Marwan Tabbara3
1 Department of Medicine, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USA 2 Katz Family Division of Nephrology, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USA 3 DeWitt Daughtry Family Department of Surgery, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USA 4 Division of Nephrology, Albany Medical College, Albany, NY, USA
Correspondence Address:
Dr. Juan C Duque Katz Family Division of Nephrology, Leonard M. Miller School of Medicine, University of Miami, Miami, FL. 33136 USA
  | Check |
DOI: 10.4103/1319-2442.248299 PMID: 30588958
|
|
Left ventricular hypertrophy (LVH) is a multifactorial complication frequently seen in patients with advanced chronic kidney disease. An arteriovenous fistula (AVF) is the preferred method for hemodialysis access. Once functional, AVFs demonstrate better patency rates and fewer complications when compared to other forms of vascular access. AVFs have been implicated in cardiac remodeling, but it is controversial whether those changes can be reversed by surgical ligation or blood flow reduction. In this study, we describe a cohort of asymptomatic patients with LVH who underwent AVF banding with a two-dimensional-echocardiogram done before and after the intervention to evaluate the association between AVF surgical banding and left ventricular mass (LVM) changes. Our results show that AVF surgical banding did not alter the left ventricular mass index (LVMI) with a mean prebanding LVMI of 70.3 ± 57.5 g/m2 and mean postbanding LVMI of 81.9 ± 55.9 g/m2, (P = 0.4). Our study shows that AVF flow reduction by surgical banding did not alter LVMI, and therefore LVH, in end-stage renal disease patients who have not yet shown clinical manifestations of cardiac disease. |
|
|
|
[FULL TEXT] [PDF]* |
|
 |
|
|